TrialHaematologica2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Srdan Verstovsek et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
90 papers cite itlatest 60 shown
this paperpooled ittrialcites it